Literature DB >> 23147729

Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.

Virginia C Gould1, Aki Okazaki, Matthew B Avison.   

Abstract

A Stenotrophomonas maltophilia mutant that coordinately hyper-expresses three resistance nodulation division-type efflux pump genes, smeZ, smeJ, and smeK, has been identified. SmeZ is responsible for elevating aminoglycoside MICs; SmeJ and SmeK are jointly responsible for elevating tetracycline, minocycline, and ciprofloxacin MICs and conferring levofloxacin resistance. One clinical isolate with this same phenotype was identified from a sample of six, and the isolate also coordinately hyper-expresses smeZ and smeJK, confirming the clinical relevance of our findings.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147729      PMCID： PMC3535947          DOI： 10.1128/AAC.01020-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.

Authors:  David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

2.  Aph(3')-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.

Authors:  Aki Okazaki; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

4.  Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia.

Authors:  T Lambert; M C Ploy; F Denis; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 5.  Antibiotic treatment of CF lung disease: from bench to bedside.

Authors:  Robert Bals; Dominique Hubert; Burkhard Tümmler
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

6.  SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships.

Authors:  Virginia C Gould; Matthew B Avison
Journal:  J Antimicrob Chemother       Date:  2006-04-05       Impact factor: 5.790

7.  Beta-lactam resistance and beta-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships.

Authors:  Virginia C Gould; Aki Okazaki; Matthew B Avison
Journal:  J Antimicrob Chemother       Date:  2005-12-13       Impact factor: 5.790

8.  Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  Role of the acetyltransferase AAC(6')-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia.

Authors:  Xian-Zhi Li; Li Zhang; Geoffrey A McKay; Keith Poole
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

10.  Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.

Authors:  Mark A Toleman; Peter M Bennett; David M C Bennett; Ronald N Jones; Timothy R Walsh
Journal:  Emerg Infect Dis       Date:  2007-04       Impact factor: 6.883
View more
  27 in total

1.  Identification of a novel 6'-N-aminoglycoside acetyltransferase, AAC(6')-Iak, from a multidrug-resistant clinical isolate of Stenotrophomonas maltophilia.

Authors:  Tatsuya Tada; Tohru Miyoshi-Akiyama; Rajan K Dahal; Shyam K Mishra; Kayo Shimada; Hiroshi Ohara; Teruo Kirikae; Bharat M Pokhrel
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

2.  SmeOP-TolCSm efflux pump contributes to the multidrug resistance of Stenotrophomonas maltophilia.

Authors:  Cheng-Wen Lin; Yi-Wei Huang; Rouh-Mei Hu; Tsuey-Ching Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

3.  Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in Stenotrophomonas maltophilia.

Authors:  Punyawee Dulyayangkul; Karina Calvopiña; Kate J Heesom; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Biolog Phenotype Microarray Is a Tool for the Identification of Multidrug Resistance Efflux Pump Inducers.

Authors:  P Blanco; F Corona; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  Vitamin K3 Induces the Expression of the Stenotrophomonas maltophilia SmeVWX Multidrug Efflux Pump.

Authors:  P Blanco; F Corona; M B Sánchez; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  The SmeYZ efflux pump of Stenotrophomonas maltophilia contributes to drug resistance, virulence-related characteristics, and virulence in mice.

Authors:  Yi-Tsung Lin; Yi-Wei Huang; Shiang-Jiuun Chen; Chia-Wei Chang; Tsuey-Ching Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

7.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activates Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia.

Authors:  Karina Calvopiña; Punyawee Dulyayangkul; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

9.  Involvement of mutation in ampD I, mrcA, and at least one additional gene in β-lactamase hyperproduction in Stenotrophomonas maltophilia.

Authors:  Asmaa Talfan; Oliver Mounsey; Matthew Charman; Eleanor Townsend; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 10.  The Potential of Phage Therapy against the Emerging Opportunistic Pathogen Stenotrophomonas maltophilia.

Authors:  Jaclyn G McCutcheon; Jonathan J Dennis
Journal:  Viruses       Date:  2021-06-03       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.